Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.

Rational, objective and design: Some cancer-protecting genes are inactivated when the EZH2 enzyme is too active or the SWI/SNF complex is less active. The EZH1/2 enzymes and the SWI/SNFs complex play opposing roles in gene expression: we hypothesize that valemetostat, an inhibitor of the EZH1/2 enzymes, will stop/slow down the growth of cancer cells by reactivating these genes. Numerous clinical trials are currently underway worldwide to optimize the development of valemetostat tosylate and potentially offer a new targeted therapeutic option for patients suffering from various cancer pathologi

Trial Details

NCT ID
NCT07303387
Phase
PHASE2
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Valemetostat Tosylate
Locations (sample)
  • Villejuif, Val de Marne, France|48.7939,2.35992
  • Bordeaux, France|44.84124,-0.58046
  • Lyon, France|45.74906,4.84789
  • Paris, France|48.85341,2.3488

Key Eligibility Criteria

  • Patient should understand, sign, and date the written informed consent form prior to any protocol-specific procedures performed.
  • Ability to comply with the protocol.
  • Age ≥ 18 years.
  • Patients must have histologically or cytologically confirmed progressive metastatic or recurrent solid tumor (as defined below for each tumor type)…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →